Therapeutic Application of Histone Deacetylase Inhibitors for Central Nervous System Disorders
核心洞察
Histone deacetylase (HDAC) inhibitors show broad therapeutic potential across multiple neurodegenerative and psychiatric disorders by modulating chromatin remodeling and gene transcription.
Preclinical studies demonstrate HDAC inhibitors can restore memory loss, ameliorate motor deficits in Huntington's disease (搜索) models, and reverse gene silencing in Friedreich's ataxia (搜索).
Brain-permeable benzamide-based HDAC inhibitors like MS-275 represent a key advancement for treating CNS disorders with regional brain selectivity.
Histone deacetylase (HDAC) inhibitors are emerging as a promising therapeutic class for central nervous system disorders, with preclinical evidence spanning neurodegenerative diseases, psychiatric conditions, and genetic syndromes. The therapeutic rationale rests on the ability of these small molecules to remodel chromatin and restore transcriptional balance in neurons affected by disease processes.
The zinc-dependent HDAC family comprises 11 members organized into distinct classes. Class I (HDACs 1, 2, 3, and 8), class IIa (HDACs 4, 5, 7, and 9), class IIb (HDACs 6 and 10), and class IV (HDAC11) exhibit unique expression patterns throughout the rat brain, as demonstrated by Broide and colleagues. Class III sirtuins (SIRT1 (搜索)–7) are NAD+-dependent deacetylases with distinct biological functions, including roles in aging and metabolism.
HDAC Inhibitors in Polyglutamine Disorders
The first demonstration of HDAC inhibitor efficacy in neurodegeneration models came from Steffan and colleagues, who showed that these agents arrest polyglutamine-dependent neurodegeneration in Drosophila. This foundational work was extended by Hockly and colleagues, who demonstrated that suberoylanilide hydroxamic acid (SAHA, vorinostat) ameliorates motor deficits in a mouse model of Huntington's disease (搜索). Ferrante and colleagues subsequently showed that sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice.
The mechanistic basis for these effects involves multiple pathways. HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress, as shown by Kawaguchi and colleagues. HDAC6 and microtubules are required for autophagic degradation of aggregated huntingtin, linking protein clearance pathways to HDAC function. Furthermore, Dompierre and colleagues demonstrated that HDAC6 inhibition compensates for the transport deficit in Huntington's disease (搜索) by increasing tubulin acetylation.
Memory, Learning, and Cognitive Disorders
Vecsey and colleagues published an important paper demonstrating that HDAC inhibitors enhance memory and synaptic plasticity via CREB:CBP-dependent transcriptional activation. This work showed restoration of memory loss by enhancing transcriptional expression of specific neuronal genes and suggested benefits of HDAC inhibitor treatment for Rubinstein–Taybi syndrome (搜索), a disorder caused by mutations in the transcriptional co-activator CBP.
Fischer and colleagues demonstrated that recovery of learning and memory is associated with chromatin remodeling, further supporting the cognitive therapeutic potential of these agents. In the context of depression, Tsankova and colleagues provided in vivo evidence of therapeutic application of HDAC inhibitors for the treatment of depression by a chromatin remodeling mechanism. Schroeder and colleagues confirmed antidepressant-like effects of the HDAC inhibitor sodium butyrate in mouse models.
Gene Silencing Disorders
Herman and colleagues showed the efficacious effect of a benzamide-based HDAC inhibitor on heterochromatin-mediated repression, resulting in transcriptional reactivation of the silenced frataxin (搜索) gene product in Friedreich's ataxia (搜索). Rai and colleagues subsequently demonstrated that HDAC inhibitors correct frataxin deficiency in a Friedreich ataxia mouse model.
In spinal muscular atrophy (搜索), Avila and colleagues showed that trichostatin A increases SMN expression and survival in a mouse model. The benzamide M344, a novel HDAC inhibitor, significantly increases SMN2 (搜索) RNA/protein levels in spinal muscular atrophy cells, as reported by Riessland and colleagues.
Rett syndrome (搜索), caused by mutations in X-linked MECP2 encoding methyl-CpG-binding protein 2, represents a landmark link between epigenetic regulation and pathology, paving the way for potential therapeutic application of HDAC inhibitors in this disorder.
Sirtuins as Therapeutic Targets
SIRT1 (搜索) activation has emerged as a neuroprotective strategy. Parker and colleagues provided genetic and pharmacological evidence relating to the protective effects of SIRT1 activation in in vivo neurodegeneration models, showing that resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons. Kim and colleagues demonstrated that SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease (搜索) and amyotrophic lateral sclerosis (搜索).
Conversely, SIRT2 (搜索) inhibition represents a distinct approach. Outeiro and colleagues provided evidence regarding the feasibility of a novel treatment approach for neurodegeneration using selective inhibitors of SIRT2, showing that SIRT2 inhibitors rescue α-synuclein-mediated toxicity in models of Parkinson's disease (搜索).
Brain-Penetrant HDAC Inhibitors
Simonini and colleagues described the application of HDAC inhibitors for the treatment of CNS disorders using MS-275, one of the first benzamide-based brain-permeable HDAC inhibitors developed. This compound demonstrated potent, long-lasting brain region-selective inhibition of histone deacetylases, representing a critical advancement for translating HDAC-targeted therapies to neurological indications.
Multiple Sclerosis (搜索) and Neuroinflammation
Camelo and colleagues demonstrated that transcriptional therapy with the HDAC inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis, a model of multiple sclerosis (搜索). Gray and Dangond provided rationale for the use of HDAC inhibitors as a dual therapeutic modality in multiple sclerosis, targeting both inflammatory and neurodegenerative components.
Stroke and Neuroprotection
In cerebral ischemia models, Ren and colleagues showed that valproic acid reduces brain damage induced by transient focal cerebral ischemia in rats, with potential roles of HDAC inhibition and heat shock protein induction. Faraco and colleagues demonstrated that pharmacological inhibition of HDACs by SAHA specifically alters gene expression and reduces ischemic injury in the mouse brain. Langley and colleagues showed that pulse inhibition of HDACs induces complete resistance to oxidative death in cortical neurons without toxicity.
The breadth of preclinical evidence across diverse CNS disorders, combined with the development of brain-penetrant isoform-selective inhibitors, positions HDAC modulation as a versatile therapeutic strategy. The field now faces the challenge of translating these robust preclinical findings into clinical efficacy for patients with devastating neurological conditions.